Jin Xu

Medical School Education

Hunan Medical University, China (1997)

Graduate School Education

Xiangya School of Medicine, Central-South University, China (1997-2000)

Residency Training

UW-Madison, Anatomical and Clinical Pathology (2013-2017)

Fellowship Training

UW-Madison, General Surgical Pathology (2017-2018)

Breast Pathology Fellowship Training: MSKCC-NYC (2018-2019)

Clinical Interests

Breast and Gynecologic Surgical Pathology

Research Interests

Implication of biomarkers, especially Her2, in breast pathology; beta-catenin associated divergent differentiation in gynecological tumors.

Selected Publications

Aysenur Keske, Sindhu Shetty, Paul S Weisman, Stephanie McGregor, Jin Xu   A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression. Pathology – Research and Practice, July 2023. Accepted for publication.

Jin Xu, Kay J Park and Paul Weisman. An Expanded Series of Pilomatrix-like High-Grade Endometrioid Carcinoma (PiMHEC), Including both MMR Deficient and MMR Proficient Cases. Int J Gynecol Path. Published online ahead of print.

Aysenur Keske, Paul S Weisman, Jin Xu. Adenosquamous carcinoma in situ of the anus: a case series. Virchows Arch. 2023 Apr 1. Published online ahead of print.

Paul Weisman, Qiqi Yu and Jin Xu. Clinicopathological characteristics of the basal subtype of Her2 positive breast cancer as defined by SOX10 positivity. Ann Diagn Pathol. 2023 Apr; 63:152087

Jin Xu, Kay J Park, William M Rehrauer and Paul Weisman. Mesonephic-Like adenocarcinoma of the ovary with extensive squamoid morular metaplasia: a case expanding the morphological spectrum of mesonephric-like neoplasia.  Virchows Arch. 2023 Mar 1. Published online ahead of print.

Paul Weisman, Qiqi Yu, Kari Wisinski and Jin Xu. Her2-positive/low-ER-positive breast carcinoma shows a response to neoadjuvant chemotherapy similar to that of Her2-positive/ER-negative breast carcinoma. Pathology-Research and Practice, 2022 Aug 24;238:154087

Wei Wang, Taja Lozar, Athena Golfinos, Denis Lee, Ellery Gronski, Ella Ward-Shaw, Mitchell Hayes, Justine Bruce, Randall Kimple, Rong Hu, Paul Harari, Jin Xu, Aysenur Keske, Paul Sondel, Megan Fitzpatrick, huy Dinh, and Paul Lambert. Role of Stress Keratin 17 in immune evasion by head and neck cancer.  Clinical Cancer Research. 2022. May 27. Published online ahead of print.

Paul Weisman, Kay J Park, Jin Xu. FIGO grade 3 endometrioid adenocarcinomas with diffusely aberrant ß-catenin expression: An aggressive subset resembling cutaneous pilomatrix carcinomas. Int J Gynecol Path. 2022 Mar 1;41(2):126-131.

Daniel R. Matson, Molly A. Accola, Les Henderson BA, Xiangqiang Shao, Vanessa L. Horner, William Rehrauer, Paul Weisman and Jin Xu. A “null” pattern of p16 immunostaining in endometrial serous carcinoma: An under-recognized and important aberrant staining pattern. Int J Gynecol Path, 2021, Aug.

Jin Xu, Paul Weisman. Dedifferentiated secretory breast carcinoma with fibrosarcomatous features harboring an ETV6-NTRK3 fusion in both components. Genes Chromosomes and Cancer. 2020; Dec 20.

Jin Xu, Kay J Park, Paul Weisman. A novel ciliated, mucin-producing variant of HPV related cervical adenosquamous carcinoma in situ: A case report. Int J Gynecol Path. 2020; Sep 17.

Paul Weisman, Qiqi Yu, Chirstopher Flynn, William Rehrauer, Jin Xu. Solid-papillary carcinoma with reverse polarity (SPCRP) harboring a novel IDH1 R132C mutation:  A case confirming the expected IDH1/IDH2 dichotomy. Human Pathology. 2020; Sep

Krystel-Whittemore M*, Jin Xu*, Brogi E, Ventura K, Patil S, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019; 177: 61-66 (*Xu J contributed equally to this work)

Hoda RS, Brogi E, Jin Xu, Ventura K, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number ≥4.0 and <6.0. Arch Pathol Lab Med. 2019 Oct 24.